From Low-Fat, High-Carb to Insulin Resistance, Fatty Liver, and Heart Disease

I recently gave a talk at a meeting with colleagues, most of them cardiologists and endocrinologists, where I, among other things, discussed the current status of diet-heart hypothesis and the possible relationship between our fear of dietary fats and the obesity epidemic. After the meeting, a senior colleague of mine, an old friend, and a … Read more

LDL-Cholesterol May Be Overestimated on a Low-Carb, High-Fat (LCHF) Diet

Elevated LDL-cholesterol (LDL-C) is common among people who adopt a low-carb, high-fat (LCHF) lifestyle. That’s why many physicians and nutritionists remain doubtful when it comes to LCHF, despite overwhelming evidence that such a dietary approach improves several other lipid parameters, usually leads to weight loss and positively affects glucose metabolism. Several studies have shown that LDL-C constitutes a major risk factor for the … Read more

Fructose Restriction – An Effective Lipid Intervention?

The association between lipid disorders and heart disease is well known. Medical checkups usually involve measurements of cholesterol and other lipid parameters, and most doctors advise their patients on how to improve their lipid pattern. Dietary interventions to lower the risk of heart disease commonly aim at reducing blood levels of cholesterol, LDL cholesterol in particular. This is … Read more

Low-Carb Diet to Treat Non-Alcoholic Fatty Liver Disease – Does It Make Sense?

Approximately 30 percent of people in the United States have a disease that is characterized by abnormal deposits of fat in the liver. The disease is not contagious, and unlike many other disorders of the liver, it is not caused by overconsumption of alcohol. It is called non-alcoholic fatty liver disease (NAFLD) and has become the leading cause of chronic liver disease … Read more

Sugar In and Sugar Out: The Modern Treatment of Type 2 Diabetes

A few days ago the results of a potentially game-changing trial on the treatment of type 2 diabetes and cardiovascular disease (EMPA-REG OUTCOME trial) were presented at an international diabetes conference in Stockholm, Sweden and simultaneously published in the New England Journal of Medicine (1). For the first time, a study has found that a drug that … Read more

RSS
Follow by Email